The NQO1/Catalase ratios demonstrated in pancreatic cancers (Fig. 1A, SF1) revealed a dramatic potential therapeutic window that can be exploited by NQO1 bioactivatable drugs, such as ARQ761 (ß-lapachone), currently in clinical trials (NCT01502800). Here, CAT is linked to familial pancreatic carcinoma.